Avanos Medical (NYSE:AVNS) Issues Quarterly Earnings Results, Beats Estimates By $0.05 EPS

Avanos Medical (NYSE:AVNS) announced its quarterly earnings data on Tuesday. The company reported $0.29 EPS for the quarter, beating analysts’ consensus estimates of $0.24 by $0.05, FiscalAI reports. Avanos Medical had a negative net margin of 67.00% and a positive return on equity of 6.21%. The firm had revenue of $180.90 million during the quarter, compared to the consensus estimate of $174.70 million. Avanos Medical updated its FY 2026 guidance to 0.900-1.100 EPS.

Avanos Medical Trading Down 1.6%

Shares of AVNS stock opened at $15.22 on Tuesday. The stock has a market cap of $706.33 million, a P/E ratio of -1.49 and a beta of 1.09. The company has a quick ratio of 1.36, a current ratio of 2.38 and a debt-to-equity ratio of 0.12. Avanos Medical has a fifty-two week low of $9.30 and a fifty-two week high of $16.63. The business has a fifty day simple moving average of $12.86 and a 200-day simple moving average of $12.02.

Hedge Funds Weigh In On Avanos Medical

Several hedge funds have recently added to or reduced their stakes in the business. Federated Hermes Inc. lifted its holdings in shares of Avanos Medical by 2.8% in the fourth quarter. Federated Hermes Inc. now owns 25,774 shares of the company’s stock valued at $289,000 after purchasing an additional 691 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in Avanos Medical by 4.3% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 26,955 shares of the company’s stock valued at $386,000 after buying an additional 1,121 shares in the last quarter. Swiss National Bank grew its holdings in Avanos Medical by 2.1% during the 4th quarter. Swiss National Bank now owns 91,500 shares of the company’s stock valued at $1,028,000 after buying an additional 1,900 shares during the last quarter. Russell Investments Group Ltd. grew its holdings in Avanos Medical by 969.3% during the 2nd quarter. Russell Investments Group Ltd. now owns 2,545 shares of the company’s stock valued at $31,000 after buying an additional 2,307 shares during the last quarter. Finally, Jane Street Group LLC increased its position in Avanos Medical by 5.8% during the second quarter. Jane Street Group LLC now owns 56,044 shares of the company’s stock worth $686,000 after buying an additional 3,062 shares in the last quarter. 95.17% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several analysts have recently commented on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Avanos Medical in a report on Monday, December 22nd. Wall Street Zen raised Avanos Medical from a “buy” rating to a “strong-buy” rating in a report on Saturday, November 8th. Finally, Zacks Research upgraded shares of Avanos Medical from a “strong sell” rating to a “hold” rating in a report on Monday, January 26th. One research analyst has rated the stock with a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Reduce”.

Avanos Medical Company Profile

Avanos Medical is a global medical technology company that develops and markets a broad portfolio of medical devices intended to improve patient outcomes in hospital, outpatient and post-acute care settings. The company’s products focus on three core therapy areas—pain management, enteral feeding and respiratory care—designed to help clinicians manage post-operative pain, deliver nutrition support and assist breathing for patients across a variety of acute and chronic conditions.

In its pain management segment, Avanos offers both non-opioid drug delivery systems and cryoanalgesia devices, including ambulatory infusion pumps and cooled radiofrequency ablation platforms.